Results 101 to 110 of about 8,428 (249)

CODEN: RJCABP LARGE SCALE PROCESS OF MESALAMINE GREEN APPROACH FOR LARGE SCALE PROCESS OF MESALAMINE: AN ANTI INFLAMMATORY AGENT

, 2009
Mesalamine 1 is as an anti inflammatory agent in treating ulcerative colitis and crohn's disease. Its benefit is believed to be due to a topical effect on the inflamed bowel.
Jaydeepkumar Lilakar, Neti Srinivasan
core  

Higher education, professional occupation, and upper socioeconomic status are associated with lower adherence to medications in patients with inflammatory bowel disease

JGH Open, 2019
Background and Aim The literature on medication adherence in patients with inflammatory bowel disease (IBD) is heterogeneous. The present study aimed to identify the rates and predictors of nonadherence to medications in IBD. Methods This cross‐sectional
Sanjeevani K Tomar, Saurabh Kedia, Namrata Singh, Ashish D Upadhyay, Nagesh Kamat, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Saransh Jain, Govind Makharia, Vineet Ahuja   +10 more
doaj   +1 more source

Mesalamine Did Not Prevent Recurrent Diverticulitis in Phase 3 Controlled Trials

, 2014
No therapy has been proven to prevent the recurrence of diverticulitis. Mesalamine has shown efficacy in preventing relapse in inflammatory bowel disease, and there is preliminary evidence that it might be effective for diverticular disease.
Kamm, Michael A, Raskin, Jeffrey B, Szalóki, Tibor, Barrett, Karen, Márquez, Juan, Schoen, Robert E, Melzer, Ehud, Jamal, M. Mazen, Streck, Paul   +8 more
core   +1 more source

Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: A double-blind, randomized study [PDF]

, 2010
Hiroaki Ito, Mitsuo Iida, Takayuki Matsumoto, Yasuo Suzuki, Yoshiyuki Aida, Toyomitsu Yoshida, Yuichi Takano, Toshifumi Hibi∥   +7 more
openalex   +1 more source

Endoscopic and clinicopathological features of segmental colitis associated with diverticulosis

DEN Open
Objectives Segmental colitis associated with diverticulosis (SCAD) has close endoscopic and pathological similarities to ulcerative colitis (UC) and Crohn's disease. Clinical data on SCAD are limited in Japan.
Kazuhiko Obata, Kan Uchiyama, Ryuzo Murai   +2 more
doaj   +1 more source

Comparison of Concomitant Mesalamine and Immunomodulator Therapy and Immunomodulator Monotherapy for Crohn’s Disease [PDF]

, 2018
Min Seob Kwak, Kyung-Jo Kim, Jae Hee Cheon, Wan Soo Kim, Jeong Mi Lee, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Byong Duk Ye, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang   +11 more
openalex   +1 more source

Mesalamine-Loaded Microsponges as a Potential Strategy for Colon-Specific Drug Delivery

, 2023
Mesalamine, a key therapeutic agent for inflammatory bowel disease (IBD), often suffers from suboptimal release and therapeutic efficacy due to premature drug release in the upper gastrointestinal tract.
Vaishnavi Sahu, Arun Patel, Shailendra Patel
core  

A hydrogen-sulfide derivative of mesalamine reduces the severity of intestinal and lung injury in necrotizing enterocolitis through endothelial nitric oxide synthase

, 2022
Brian D. Hosfield, Chelsea Hunter, Hongge Li, Natalie A. Drucker, Anthony R. Pecoraro, Krishna Manohar, W. Christopher Shelley, Troy A. Markel   +7 more
openalex   +2 more sources

Translational Modeling of Gut Microbiome‐Mediated Drug Metabolism: A Case Example of Sulfasalazine

CPT: Pharmacometrics & Systems Pharmacology
The gut microbiome can contribute to drug metabolism and significantly influence pharmacokinetic (PK) behavior. Sulfasalazine is well‐known to be metabolized by gut bacterial azoreductases into sulfapyridine and mesalamine.
Lisa Cheng, Jingwei Cai, Alexis Auster, Sungjoon Cho, Mary Keir, Horace Rhee, Bennett Kapili, Dari Shalon, Miaoran Ning   +8 more
doaj   +1 more source

Mesalamine-Induced Myopericarditis: A Case Report and Literature Review

, 2019
Inflammation of the myocardium (myocarditis) or pericardium (pericarditis) or both (myopericarditis) as side effects of mesalamine, a drug widely used in the treatment of inflammatory bowel disease, is a rare, but potentially lethal complication.
Al-Khafaji, Jaafar, Malik, Samira, Abdalla, Abubaker O., Taha, Mohamed E.   +3 more
core   +1 more source